UroGen Pharma (URGN) Q4 2025 earnings review
ZUSDURI Launch Ignites Revenue as J-Code Catalyst Arrives
UroGen delivered a standout fourth quarter, driving total revenue up 54% YoY to $37.8 million. The core story is the sudden acceleration of ZUSDURI, which generated an implied $14.0 million in Q4—shattering Q3's slow $1.8 million start, even before the permanent J-Code took effect on January 1, 2026. A new $200 million debt refinancing eliminates near-term cash concerns, providing ample runway to scale the commercial organization. While the foundational JELMYTO business is stabilizing with decelerating growth guided for 2026, ZUSDURI's early trajectory suggests the company's multi-billion dollar market thesis is playing out.
🐂 Bull Case
The massive Q4 ramp in ZUSDURI sales ($14M vs $1.8M in Q3) proves that operational and reimbursement hurdles are already clearing. With the permanent J-Code now active, community urologist adoption should accelerate further.
UGN-103 (next-gen ZUSDURI) delivered a 77.8% CR rate in the UTOPIA trial, virtually identical to its predecessor. With an NDA on track for H2 2026, UroGen is successfully executing its IP lifecycle strategy.
🐻 Bear Case
JELMYTO Q4 revenue dipped slightly YoY ($23.8M vs $24.6M in 24Q4), and FY26 guidance implies a decelerating 3-7% growth rate. The legacy product may be reaching peak market penetration.
Total operating expenses are guided to accelerate to $240M-$250M in FY26. ZUSDURI must maintain aggressive momentum to offset the cash burn and eventually achieve profitability.
⚖️ Verdict: 🟢
Bullish. The overriding concern from last quarter—that ZUSDURI's launch was hampered by reimbursement friction—was resoundingly answered in Q4. Combined with a refinanced balance sheet, the commercial transition is working.
Key Themes
ZUSDURI Adoption Accelerating Dramatically
After a sluggish Q3 where management blamed a 45-60 day lag in claims processing for generating just $1.8M in revenue, Q4 delivered a massive reversal. ZUSDURI netted an implied $14.0M in the final quarter of 2025. Cumulatively, activated sites jumped from 592 in October to 838 by year-end, while unique prescribers nearly doubled from 54 to 102. This was achieved before the permanent J-Code (J9282) went live on Jan 1, 2026, suggesting that the underlying demand is exceptionally strong.
Balance Sheet Overhang Reversing
A key concern for investors was the company's cash runway amid scaling expenses. UroGen directly addressed this by refinancing its term loan with Pharmakon Advisors in February 2026. Retiring the old $125M facility and drawing a new $200M tranche adds non-dilutive capital to the balance sheet. This bridges the gap to sustained commercial profitability without imminent equity dilution.
UGN-103 Execution Remains Stable
UroGen's franchise longevity depends on transitioning patients from ZUSDURI to the next-generation UGN-103, which offers simpler preparation and extended patent life. The UTOPIA trial confirmed a 77.8% 3-month complete response rate, mirroring the ENVISION trial data that got ZUSDURI approved. The FDA has agreed to accept this for an NDA filing in the second half of 2026.
JELMYTO Growth Decelerating
While total FY25 JELMYTO sales hit $94.0M (+7% underlying demand growth YoY), the Q4 trajectory showed flattening momentum. Implied Q4 JELMYTO revenue was $23.8M, essentially flat to slightly down versus $24.6M in 24Q4. The FY26 guidance for JELMYTO of $97-$101M suggests management expects market saturation to cap growth at just 3-7%.
Operating Expenses Accelerating
Building a multiproduct commercial organization is costly. FY25 total operating expenses hit $222.2M, up from $178.3M in FY24. With FY26 guidance targeting $240M-$250M, UroGen is committed to aggressive spending to seize the ZUSDURI market opportunity. If the post-J-Code ZUSDURI ramp underwhelms, this high fixed-cost base will punish margins.
Other KPIs
Accelerating significantly alongside top-line revenue, up from $22.1 million in Q4 2024. The massive 91% gross margin achieved in Q4 reflects the high-value pricing of ZUSDURI and JELMYTO flowing cleanly to the gross profit line.
Reversing the widening trend. Thanks to the outsized revenue beat from ZUSDURI, Q4 net loss narrowed meaningfully compared to $(0.80) in the prior year period and $(0.69) in Q3 2025. This shows early signs of operating leverage.
Accelerating from $121.2M in FY24, primarily driven by the ZUSDURI commercial sales force expansion. UroGen has transitioned from a niche rare-disease operator to a broad community oncology commercial entity.
Guidance
Decelerating. Implies a year-over-year growth rate of 3% to 7%, a step down from the 7% underlying demand growth achieved in FY25. Indicates the legacy asset is becoming a stable cash cow rather than a growth engine.
Accelerating versus the $222.2 million reported for FY25. Includes $20M to $24M in non-cash stock compensation. Driven by full-year impact of the expanded 80+ rep ZUSDURI salesforce and ongoing UGN-103/104 Phase 3 clinical trials.
Management explicitly withheld full-year ZUSDURI guidance citing the early stages of commercial launch, though the $14M implied Q4 exit rate sets a formidable floor for 2026 modeling.
Key Questions
ZUSDURI Revenue Mix
With ZUSDURI revenue jumping to ~$14M in Q4, how much of this was a one-time flush of pent-up demand/backlogged patients resolving versus recurring organic prescription growth?
J-Code Impact on Reimbursement Timing
Now that the permanent J-Code is active, what specific reductions in the 45-60 day claim-to-dosing lag time are you observing in Q1?
JELMYTO Deceleration
Does the 3-7% growth guidance for JELMYTO reflect a natural ceiling in the UTUC market, or are you seeing any cannibalization/distraction of physician mindshare by the ZUSDURI launch?
UGN-103 Migration Strategy
With UGN-103 targeting an NDA in H2 2026, how will the commercial team manage the impending transition to ensure ZUSDURI's momentum isn't stalled by physicians waiting for the improved formulation?